

Q1 Performance In Initiating 2018 2019

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
17/SC/0039	220282	MEO4-002 - Methoxyflurane Anaesthesia for Paediatric Injuries (MAGPIE)	Yes	10/01/2018	28/07/2017	28/07/2017	18/04/2017	05/09/2017	12/09/2017	Please Select...	25/10/2017	E - Staff availability issues H - Contracting delays	70 Day Target Date Not Met. Contracting and Site Staffing Delays	Both
17/LO/1245	208149	Metronidazole Versus lactic acid for Treating bacterial vAgnosis-VITA	Yes	29/11/2017	20/09/2017	20/09/2017	12/09/2017	30/10/2017	09/11/2017	Please Select...	13/11/2017	D - Sponsor Delays F - No patients seen	70 Day Target Date Not Met. Draft CTA received 23.10.2017. Sponsor took CTA with them from the Siv on 31.10.2017. Fully executed CTA was still awaited on 13.11.2017, when CBC was issued. Green light received from Sponsor on 17.11.2017. Study difficult to recruit to because only c.8.5% of potential participants are eligible.	Sponsor
17/LO/1363	226980	Safety and Efficacy of Two TAVI Systems	Yes	29/11/2017	24/10/2017	24/10/2017	31/10/2017	18/09/2017	27/10/2017	Please Select...	23/11/2017	J - Other	70 Day Target Date Met	Neither
14/SW/1061	131169	CTLA4 Ig (Abatacept) for prevention of abnormal glucose tolerance and diabetes in relatives at risk for Type 1 diabetes mellitus	No		22/09/2017	22/09/2017	13/11/2017	18/09/2017	05/12/2017	Please Select...	15/01/2018	J - Other	Sponsor and site agreed that the study would start in Jan 2018 due to the potential participant's care pathway. One potential participant approached, was a screen failure.	Neither
17/EM/0371	229496	SMART CRT_C2067_Boston Scientific_Heart Failure	Yes	09/03/2018	23/06/2017	30/11/2017	21/11/2017	26/09/2017	03/10/2017	Please Select...	18/12/2017	D - Sponsor Delays F - No patients seen	The sponsor changed essential documents after capacity and capability was issued. No eligible patients seen within the 70 day recruitment window, FPR recruited 08th March 2018	Sponsor
17/HH/0076	208944	CALM- DIEM – CONTROLLING AND LOWERING BLOOD PRESSURE WITH THE MOBUSHOP – DEFINING EFFICACY MARKERS	Yes	13/12/2017	04/07/2017	05/07/2017	18/05/2017	17/10/2017	24/10/2017	Please Select...	25/10/2017	A - Permissions delayed/denied D - Sponsor Delays	70 Day Target Date Not Met. Delays from the sponsors end re costings, correct costings information received on 06.10.2017. Sponsor delay in sending regulatory approval letter for PIS. Site delays re IRMER queries.	Both
17/EM/0241	223736	FRED Registry Study	Yes	23/11/2018	28/08/2017	28/08/2017	08/08/2017	12/12/2017	12/12/2017	Please Select...	05/11/2017	A - Permissions delayed/denied F - No patients seen	70 Day Target Date Not Met. IRMER Section B Form Missing which Delayed IRMER Approvals. No eligible patients seen.	NHS Provider
17/EE/0431	234555	A Phase 2b, Randomized, Double-Blind, Active-Comparator-Controlled, Dose- Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination with Doravirine (DOR) and Lamivudine (3TC) in HIV-1- Infected Treatment-Naive Adults	Yes	09/02/2018	05/10/2017	26/10/2017	18/12/2017	22/12/2017	04/01/2018	Please Select...	09/01/2018	A - Permissions delayed/denied D - Sponsor Delays H - Contracting delays	70 Day Target Not Met. Sponsor did not have a European lab manual available, needed to reimburse the PIS V2.0 on 24th Nov 2017 and did not provide HRA approval letter to site until 5th December 2017. Contracting delays - sponsor contacts for contracts and finances were different which resulted in some communication delays relating to the CTA.	Both
17/LO/0825	223457	Randomised, Phase 2, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in adult subjects with active sjogren's syndrome.	Yes	08/11/2017	21/03/2017	05/07/2017	30/06/2017	07/08/2017	15/08/2017	Please Select...	13/09/2017	F - No patients seen	5 patients screened but of those only one was booked for screening and potential consent. No eligible patients seen.	Neither
17/LO/1091	229631	A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682-B (Grazoprevir/ Ruzarvir /Uprfosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infection (MK-3682 Protocol 037)	No		13/07/2017	13/07/2017		20/07/2017	20/07/2017	Sponsor declined site confirmation		B - Suspended by sponsor	Sponsor cancelled the study at all sites globally as it was discontinuing investigation into the IMP as a result of Phase 2 efficacy data and growing treatment options for the prospective patient group. No information available re the date of HRA approval	Neither
15/NS/0113	188563	The clinical and cost effectiveness of surgical interventions for stones in the lower kidney: the PURE RCT Percutaneous Nephrolithotomy (PNL), Flexible Ureteroscopy (FURS) and Extracorporeal Lithotripsy (ESWL) for lower pole kidney stones.	Yes	24/04/2018	27/07/2017	27/07/2017	13/06/2016	29/08/2017	12/09/2017	Please Select...	18/10/2017	G - No patients consented	70 Day Target Not Met. 3 participants approached before the 70 Day Target, all of whom Declined.	Neither
17/LO/0736	225746	A randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986158 in Participants with Progressive Supranuclear Palsy (CN02012)	Yes	27/02/2018	03/02/2017	25/09/2017	21/07/2017	28/09/2017	25/09/2017	Please Select...	08/12/2017	D - Sponsor Delays	70 Day Target Not Met. Sponsor delays in providing essential information to pharmacy	Sponsor
16/LO/2079	215192	EDMOND – A feasibility study of Elemental Diet as an alternative to parenteral nutrition for patients with inoperable Malignant bowel Obstruction	Yes	12/02/2018	09/10/2017	09/10/2017	20/02/2017	06/02/2018	06/02/2018	Please Select...	06/02/2018	D - Sponsor Delays	70 Day Target Date Not Met. Study sponsor delays in confirming they still wanted additional sites, the sponsor wished to make some amendments, and then in confirming site initiation visit date.	Sponsor
17/LO/1519	230794	A Prospective, Multicenter, Non-Randomized, Single-Arm, Open-Label Clinical Study to Evaluate the Safety and Feasibility of the Leaflex™ Performer (The Leaflex™ Performer Feasibility Study)	Yes	13/06/2018	06/11/2017	06/11/2017	01/11/2017	31/01/2018	02/02/2018	Please Select...	24/04/2018	D - Sponsor Delays	70 Day Target Date Not Met. Study Not Open to Recruitment at Data Cut Off Point due to Sponsor Delays in changing study device design during set up.	Sponsor
16/LO/1979	193891	A randomised trial of non-Selective versus selective adjuvant Therapy in high risk Apparent Stage 1 Endometrial Cancer	Yes	07/03/2018	06/11/2017	06/11/2017	20/12/2016	15/01/2018		Site declined to participate		A - Permissions delayed/denied	The site declined to participate in this study as there were clinical reasons the site felt they would not be able to deliver recruits to this study.	Neither
17/EE/0429	234063	A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lemicicabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected with Respiratory Syncytial Virus	No		14/11/2017	14/11/2017				Site declined to participate		A - Permissions delayed/denied	The site declined to participate due to it being the wrong season for recruitment (Spring rather than Winter) and subsequently when the sponsor re-offered the study they updated site that study was currently on hold	Neither
14/WS/1096	149204	Shortcourse radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a leadin phase I dose escalation study.	No		21/11/2017	21/11/2017	03/11/2014	04/01/2018	18/01/2018	Please Select...	17/04/2018	E - Staff availability issues	Delays with local IRMER approvals due to staffing capacity issues at site. Site not ready to start at data cut off point.	NHS Provider
17/EE/0382	220851	PROFILE - personalised medicine in Crohn's disease	No		11/12/2017	02/01/2018	02/11/2017	30/01/2018	07/02/2018	Please Select...	24/05/2018	D - Sponsor Delays G - No patients consented	70 Day Target Not Met. Sponsor submitted an amendment during set up. Site not ready to recruit at data cut off timepoint, sponsor had not confirmed at data cut off point. 70 Day Target Not Met. Delays with IRMER and pharmacy department confirmation of C.R.C. Eligible patients seen but did not consent.	Sponsor
17/LO/2058	231907	A PROSPECTIVE, MULTICENTER, NON-RANDOMIZED, POST-MARKET CLINICAL FOLLOW-UP STUDY TO CONFIRM SAFETY AND PERFORMANCE OF THE COHERE WAVECREST™ LEFT ATRIAL APPENDAGE OCCLUSION SYSTEM IN CURRENT MEDICAL PRACTICE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION WAVECREST PMCF STUDY - CHX_IP015	Yes	07/03/2018	16/10/2017	02/01/2018	08/01/2018	07/12/2017	11/12/2017	Please Select...	01/03/2018	J - Other	70 Day Target Met	Neither
17/EE/0448	226368	Randomised Controlled Trial of Cryo Ablation versus Cardioversion in Persistent Atrial Fibrillation	Yes	08/03/2018	17/08/2017	14/01/2018	19/12/2017	16/11/2017	23/02/2018	Please Select...	26/02/2018	J - Other	70 Day Target Met, 3 patients recruited and randomised by the recruitment target date	Neither
17/SC/0164	210735	A multi-centre, randomised, controlled trial evaluating the effects of early high-dose cryoprecipitate in adult patients with major trauma haemorrhage requiring major haemorrhage protocol (MHP) activation	No		22/11/2017	01/02/2018	26/05/2017	18/12/2017	19/02/2018	Please Select...	16/03/2018	J - Other	Still within the 70 Day Recruitment Window	Neither

16/NW/0629	211995	The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of fluoxacinil as a long-term prophylaxis agent for infants with CF.	No		09/02/2018	09/02/2018	22/09/2016	13/03/2018	26/03/2018	Please Select...	16/04/2018	J - Other	J - 70 Day Target Not Met. FFR 30 Day Target was 26/05/2018, not met. Rare patient group, sponsor sent us the HRA pack too early. Recruitment target for this study is 1 participant in total. CSC issued 16/04/2018. SVI took place 24/04/2018.	Neither
17/SW/0255	234748	Clinical Trial Evaluation of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System	No		22/02/2018	22/02/2018				Please Select...		D - Sponsor Delays	Sponsor changed the protocol which affected ionising radiation risk assessments, meaning the study required re-review by regulatory authorities. Approvals awaited at cut off time point	Sponsor
17/NS/0018	223787	Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study); a superiority randomised clinical trial to evaluate the effectiveness and cost effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms.	No		05/03/2018	05/03/2018	27/02/2018	23/04/2018	27/04/2018	Please Select...	27/04/2018	F - No patients seen	70 Day Target Not Met. Referrals have reduced due to a national mesh scare.	Neither
17/LL/2093	228763	A phase IV, open-label pilot study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving OBT plus maraviroc or OBT	Yes	06/04/2018	24/11/2017	19/03/2018	28/02/2018	19/03/2018	27/03/2018	Please Select...	28/03/2018	J - Other	70 Day Recruitment Target Met	Neither
17/EM/0281	220954	204862 Phase 3 switch study -TAF regimen to DTG + 3TC in HIV-1 adults	Yes	24/04/2018	21/07/2017	18/08/2017	15/02/2018	02/08/2017	16/08/2017	Please Select...	29/03/2018	D - Sponsor Delays	70 Day Target Date Not Met. Patient recruited two days after 30 day recruitment target date. Sponsor delays in issuing documentation to start the study.	Sponsor
18/WM/0017	236521	Post-Market Clinical Investigation of the Clareon® IOL	Yes	04/06/2018	09/01/2018	16/02/2018		16/04/2018	18/04/2018	Please Select...	16/12/2018	D - Sponsor Delays	70 Day Target Not Met. First patient recruited within 17 days of site activation. Set up was delayed due to staffing changeover at site. The sponsor only wanted the site open from Q2 2018	Sponsor
17/EM/0361	234065	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies	No		28/06/2017	12/01/2018	11/01/2018	05/02/2018	19/02/2018	Please Select...	21/03/2018	D - Sponsor Delays G - No patients consented	70 Day Target Not Met. Sponsor changed pharmacy relevant information when site were close to opening and pharmacy SOPs had to be re-written, also requested that the site participate in additional training sessions. 5 patients approached and of those which weren't screening failures, potential participants didn't want to take part in the extra research	Sponsor
16/LO/1905	195890	A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (REACT)	Yes	23/04/2018	07/01/2018	12/04/2018	31/03/2017	28/03/2018	28/03/2018	Please Select...	13/04/2018	J - Other	70 Day Target Date Met. 3 patients recruited to date.	Neither
17/NI/0204	230772	Nordic-Baltic-British Study on Optical Coherence Tomography Optimized Bifurcation Event Reduction	No		04/12/2017	19/04/2018	05/04/2018	28/06/2018	28/06/2018	Please Select...	10/07/2018	D - Sponsor Delays	70 Day Target Not Met. Delays in receiving documents from study sponsor. To recruit first patient by 28th July 2018.	Sponsor
18/SC/0155	236211	A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPagliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease	No		23/04/2018	23/04/2018	26/04/2018			Please Select...		J - Other	70 Day Target Date Not Met. Sponsor and Site had agreed a later start date.	Neither
16/NS/0106	212541	Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy - A randomised trial (RAACINO)	No		09/03/2018	08/05/2018	04/04/2017	17/04/2018	07/05/2018	Please Select...	08/05/2018	G - No patients consented	70 Day Target Not Met. This study is screening a large number of patients. 6 patients approached but none consented yet.	Neither
17/LO/0731	219463	A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost	Yes	29/06/2018	23/11/2017	23/05/2018	27/07/2017	17/01/2018	08/01/2018	Please Select...	19/06/2018	J - Other	70 Day Target Met	Neither
18/NI/0132	242937	A PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB & CHEMOTHERAPY IN PATIENTS WITH HER2 POSITIVE EARLY BREAST CANCER	No		27/02/2018	24/05/2018	07/06/2018	25/05/2018	07/06/2018	Please Select...	24/07/2018	J - Other	Still within the 70 Day Recruitment Window. A patient is due for screening and potentially consenting on 03/08/2018	Neither
17/YH/0228	223492	CALM- 2 – CONTROLLING AND LOWERING BLOOD PRESSURE WITH THE MOBUSHIP®	No		15/02/2018	12/06/2018	05/10/2017	03/05/2018	04/05/2018	Please Select...	13/06/2018	F - No patients seen	70 Day Target Not Met. Over 150 patients screened so far, none currently eligible.	Neither